UCB SA (UCB.BR) Stock Price, Quote, News and Overview
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
UCB.BR Quote, Performance and Key Statistics
UCB SA
EBR:UCB (2/5/2025, 9:43:19 AM)
183.35
-1.15 (-0.62%)
The current stock price of UCB.BR is 183.35 EUR. In the past month the price decreased by -3.5%. In the past year, price increased by 96.95%.
UCB.BR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 81.35 | 759.93B | ||
| 1LLY.MI | ELI LILLY & CO | 79.43 | 741.99B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.22 | 413.69B | ||
| NOV.DE | NOVO NORDISK A/S-B | 29.13 | 367.38B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.25 | 355.12B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| SAN.PA | SANOFI | 14.5 | 256.01B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.16 | 220.84B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B |
Related stock screener links
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,083 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9083
Company Website: https://www.ucb.com
Investor Relations: https://www.ucb.com/investors/
Phone: 3225599999
UCB.BR FAQ
What is the stock price of UCB.BR?
The current stock price of UCB.BR is 183.35 EUR.
What is the symbol for UCB SA stock?
The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.
On which exchange is UCB.BR stock listed?
UCB.BR stock is listed on the Euronext Brussels exchange.
Is UCB.BR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for UCB.BR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of UCB.BR.
Does UCB.BR stock pay dividends?
UCB.BR has a dividend yield of 0.5%. The yearly dividend amount is currently 1.33.
When does UCB.BR stock report earnings?
UCB.BR will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of UCB.BR?
The PE ratio for UCB.BR is 50.1. This is based on the reported non-GAAP earnings per share of 3.66 and the current share price of 183.35 EUR.
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 98.21% of all stocks.
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UCB.BR. Both the profitability and financial health of UCB.BR have multiple concerns.
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 3.66. The EPS decreased by -4.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.4% | ||
| ROA | 1.54% | ||
| ROE | 2.68% | ||
| Debt/Equity | 0.33 |
UCB.BR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to UCB.BR. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of 3.49% and a revenue growth 12.34% for UCB.BR